TABLE 1.

Characterization of strains used in the present study

Strain(s)a	Clarithromycin MIC (μg/ml)	23S mutation(s) detected by:
		Conventional methodsb	PCR-LiPA
C3II	>256	WTc	WT
1714, 1309, 1462, 11496	<2	WT	WT
1578–96, H2, 71, 35888, 1759, 11, 1710, 10, 1307, 1403, 1295, 2595, 2577, AB G1-2	>256	A2142G	A2142G
1066–97, 7, 8, AB1125, CB1159, HS1146	4–128	A2142G	A2142G
1467, AB C1-5	>256	A2142C	A2142C
AB T1-2	16	A2142T	A2142T
82, 1190, 1213, 1289, 1315, 1377, 1388, 1392, 1394, 1401, 1553, MOR, FERA	>256	A2143G	A2143G
4, 15, 333, 34319, MARJE, MIS, AB G2-3	4–64	A2143G	A2143G
AB C2-5	16	A2143C	A2143C
1538	>256	WT + A2143G	WT + A2143G
1470	>256	A2142G	A2142G + A2143G + WT
LINAN 1567	>128	A2142C + A2143G + WT	A2142C + A2143G + WT
PAP	16	WT + A2142G	WT + A2142G
140–97	<2–>256	WT	WT + A2142G + A2143G
1264	>256	A2142G	A2142G + A2143G
1075	>256	A2143G	A2142G + A2143G
AB T2-16	<1	A2143T + WT	WT

^aLaboratory-derived artificial strains are underlined. 

^bConventional methods included direct sequence analysis, RFLP, and probe hybridization in liquid phase. 

^cWT, wild type.